London, United Kingdom, January 25, 2018 --(PR.com
)-- Presenting issues and real-life examples within the RNA space, SMi welcome insights and discussions into new technologies for single-stranded RNA, epigenetics to develop first-inclass drugs in oncology, patenting RNA Therapeutics and exploring the latest developments in delivery systems, including Exosomes and Nanocomplexes.
The Keynote Address on day 1 will be presented by Paul Agris, Founding Director & Professor at The RNA Institute. Gain a deeper insight into his presentation "Engineering a Novel Antibiotic Against a Unique RNA Target that Prevents Resistance." His session will be looking at how novel antibiotics can bind to target RNA and prevent resistance with low cytotoxicity and toxicity.
Summary of presentation:
- Target selection unique to Gram positive pathogens
- Screening tools for putative small molecule, RNA binding antibiotics against Gram positive pathogens and their biofilms
- Target prevents emergence of resistance
- Low Cytotoxicity and Toxicity
The Opening Address on day 2 will be presented by Kirsty Wydenbach, Senior Medical Assessor, Deputy Unit Manager, Clinical Trials Unit, at MHRA. Her presentation "Gaining Regulatory Approval and Mitigating Risks during Clinical Trials" will explore how best to gain regulatory approval and clinical success through overcoming common governing pitfalls and understanding the expectations of regulators.
Summary of presentation:
- Expectations of a regulator and how to report your results
- Overcoming common governing pitfalls
- Updates of new and upcoming regulations and how you may be affected
- Meet future connections face-to-face
Not only will RNA Therapeutics highlight the newest clinical techniques and provide exposure to the latest technology and products, it will also place face to face with influential people who can help build a solid foundation in several key areas including new ocular drugs, therapies for glaucoma, clinical results from long /short term studies and more.
- New Innovation
Shire's approach to meet unmet ophthalmic needs has been successful by developing lifitegrast, after being evaluated in four clinical trials. They have plans filing lifitegrast in multiple global markets by the end of 2017.
- Benefit from interactive formats
Examine real-life case studies exploring clinical results from four 12-week efficacy and safety studies, and one long term (1-year) safety study and discovering unique properties to preservative free drugs.
Further information is available at: www.therapeutics-rna.com/prc
SMi presents the 9th Annual Conference:
Date: 21st – 22nd February 2018
Location: Holiday Inn London - Kensington Forum
Sponsored by: ChemGenes | Phion Therapeutics | Advanced Cell Diagnostics | Lypocalyx
For all media inquiries contact Pavan Solanki on Tel: +44 (0)20 7827 6048 / Email: firstname.lastname@example.org
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk